Belhaven BioPharma Intranasal Dry Powder Epinephrine Patent Application
Summary
Belhaven BioPharma Inc. filed patent application US20260108688A1 for intranasal dry powder epinephrine compositions including a stabilizing agent (citric acid or salt) and carrier, dated October 29, 2025. The application covers methods for treating health conditions threatening the central nervous system including anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events. Inventors are Scott Lyman and Brian Taubenheim.
“Intranasal dry powder epinephrine compositions are described herein.”
About this source
USPTO classification A61M covers devices that introduce or withdraw fluids from the body: infusion pumps, catheters, syringes, inhalers, wound drainage, dialysis equipment, and fluid-handling microfluidics. Every newly published application in A61M lands in this feed, around 205 a month. Applications publish 18 months after filing. Watch this if you compete in infusion therapy or drug delivery, file freedom-to-operate analyses for medical device startups, scout acquisition targets in cardiovascular or respiratory devices, or track hospital R&D arms that are quietly patenting clinical innovations.
What changed
Belhaven BioPharma Inc. filed patent application US20260108688A1 with the USPTO on October 29, 2025, covering intranasal dry powder epinephrine compositions combined with citric acid or a salt as a stabilizing agent and a carrier. The application identifies specific therapeutic uses including anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events.
Pharmaceutical and medical device companies developing epinephrine delivery systems should review this application to assess potential patent landscape implications for intranasal dry powder formulations. Competitors in the anaphylaxis treatment space may need to design around these claims or evaluate licensing opportunities with Belhaven BioPharma.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE
Application US20260108688A1 Kind: A1 Apr 23, 2026
Assignee
Belhaven BioPharma Inc.
Inventors
Scott Lyman, Brian Taubenheim
Abstract
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
CPC Classifications
A61M 15/08 A61K 9/0043 A61K 31/137 A61K 47/12 A61K 47/26 A61M 11/003 A61M 11/007
Filing Date
2025-10-29
Application No.
19372926
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Medical Devices (A61M)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Medical Devices (A61M) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.